<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13172">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00420628</url>
  </required_header>
  <id_info>
    <org_study_id>459</org_study_id>
    <nct_id>NCT00420628</nct_id>
  </id_info>
  <brief_title>Pediatric Zylet Safety and Efficacy Study</brief_title>
  <official_title>A Safety and Efficacy Study of ZyletÂ® (Loteprednol Etabonate 0.5% and Tobramycin 0.3% Ophthalmic Suspension) Compared to Vehicle in the Management of Lid Inflammation (Chalazion/Hordeolum) in Pediatric Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bausch &amp; Lomb Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bausch &amp; Lomb Incorporated</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicenter study to evaluate the safety and efficacy of Zylet compared to vehicle in
      children aged 0-6 for the management of lid inflammation (chalazion/hordeolum)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Treatment Emergent Adverse Events</measure>
    <time_frame>day 1, day 8, day 15</time_frame>
    <safety_issue>No</safety_issue>
    <description>Study eye - Safety Population, At all visits 1,2,3</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Investigators Global Assessment of the Clinical Condition</measure>
    <time_frame>Visit 3, day 8</time_frame>
    <safety_issue>No</safety_issue>
    <description>The efficacy endpoints for this study consisted of reduction of inflammation as measured by the IGA of the clinical condition. Changes in clinical condition measured as improved, unchanged or worsened.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Ocular Signs in the Study Eye - Visit 1</measure>
    <time_frame>Visit 1 (day 1)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Lid edema, lid erythema, palpebral conjunctival injection, meibomium plugging measured on a scale of 0-4 none, minimal, mild, moderate, severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Ocular Signs in the Study Eye - Visit 2</measure>
    <time_frame>Visit 2 (day 8)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Lid edema, lid erythema, palpebral conjunctival injection, meibomium plugging measured on a scale of 0-4 none, minimal, mild, moderate, severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Ocular Signs in the Study Eye - Visit 3</measure>
    <time_frame>Visit 3 (day 15)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Lid edema, lid erythema, palpebral conjunctival injection, meibomium plugging measured on a scale of 0-4 none, minimal, mild, moderate, severe.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">108</enrollment>
  <condition>Chalazion</condition>
  <condition>Hordeolum</condition>
  <arm_group>
    <arm_group_label>Loteprednol/Tobramycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5% loteprednol etabonate with 0.3% tobramycin opthalmic suspension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>loteprednol etabonate/tobramycin opthalmic suspension</intervention_name>
    <description>Topical ophthalmic drug: 0.5% loteprednol etabonate with 0.3% tobramycin 4 times a day (QID) days 1-7, 2 times a day (BID) days 8-14. Warm compresses were applied to affected eyes 2 times a day prior to application of study medication.</description>
    <arm_group_label>Loteprednol/Tobramycin</arm_group_label>
    <other_name>Zylet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vehicle</intervention_name>
    <description>topical ophthalmic vehicle was applied 4 times a day (QID) days 1-7, 2 times a day (BID) days 8-14. Warm compresses were applied to affected eyes 2 times a day prior to application of study medication.</description>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Child, 0 to 6 years of age, any sex and race

          -  Subject must have a clinical diagnosis of lid inflammation (e.g. Chalazion/Hordeolum)
             in at least one eye. If both eyes are diagnosed with lid inflammation, both eyes will
             be treated

          -  In good health (no current or past relevant medical history), based on the judgment
             of the investigator

          -  Parent/guardian is able and willing to follow instructions and provide informed
             consent

        Exclusion Criteria:

          -  Known hypersensitivity to corticosteroids, loteprednol etabonate, or any component of
             the study medication

          -  Known hypersensitivity to aminoglycosides, tobramycin, or any component of the study
             medication

          -  Use of concurrent ocular therapy with non-steroidal anti-inflammatory agent (NSAID),
             mast cell stabilizer, antihistamine, or decongestant within 48 hours before and
             during the study

          -  Use of oral or topical ophthalmic corticosteroids (other than study medication)
             within 48 hours before and during the study

          -  Use of systemic antibiotics within 72 hours before and during the 14 day study
             medication treatment duration

          -  Use of topical ophthalmic antibiotics (other than the study medication) within 72
             hours before and during the study

          -  History of ocular surgery, including laser procedures, within the past six months

          -  Anticipation that surgical intervention for lid inflammation will be required prior
             to completion of the study

          -  Subjects with suspected vernal conjunctivitis, glaucoma of any kind, viral or
             bacterial conjunctivitis, preseptal cellulitis requiring systemic antibiotics,
             dacryocystitis, uveitis, or any other disease conditions that could interfere with
             the safety and efficacy evaluations of the study medication

          -  History of any severe/serious ocular pathology or medical condition that could result
             in the subject's inability to complete the study

          -  Participation in an ophthalmic drug or device research study within 30 days prior to
             entry in this study

          -  Unlikely to comply with the protocol instructions for any reason
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>6 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy L Comstock, OD</last_name>
    <role>Study Director</role>
    <affiliation>Bausch &amp; Lomb Incorporated</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pediatric Ophthalmology of Erie</name>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <zip>16501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <lastchanged_date>September 30, 2011</lastchanged_date>
  <firstreceived_date>January 8, 2007</firstreceived_date>
  <firstreceived_results_date>March 19, 2010</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Chalazion</mesh_term>
    <mesh_term>Hordeolum</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Loteprednol etabonate</mesh_term>
    <mesh_term>Tobramycin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>108 subjects aged 0-6 years with lid inflammation were recruited from 15 clinic locations in the US. First subject was enrolled on 11/07/2006, last subject visit was 1/5/2009.</recruitment_details>
      <pre_assignment_details>108 subjects were randomized to receive loteprednol/tobramycin or its vehicle in a 2:1 ratio. Subjects will receive warm compress lid treatment 2 times daily, before administration of study medication (as applicable) for the 14-day treatment duration.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Loteprednol/Tobramycin</title>
          <description>0.5% loteprednol etabonate with 0.3% tobramycin opthalmic suspension administered into affected eye(s) for 14 days</description>
        </group>
        <group group_id="P2">
          <title>Vehicle</title>
          <description>Vehicle used in the study drug administered into affected eye(s) for 14 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="72"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="63"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawn by parent or gaurdian</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Loteprednol/Tobramycin</title>
          <description>0.5% loteprednol etabonate with 0.3% tobramycin opthalmic suspension administered into affected eye(s) for 14 days</description>
        </group>
        <group group_id="B2">
          <title>Vehicle</title>
          <description>Vehicle used in the study drug administered into affected eye(s) for 14 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="72"/>
                <measurement group_id="B2" value="36"/>
                <measurement group_id="B3" value="108"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Age 0-6 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="72"/>
                <measurement group_id="B2" value="36"/>
                <measurement group_id="B3" value="108"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="37"/>
                <measurement group_id="B2" value="23"/>
                <measurement group_id="B3" value="60"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="35"/>
                <measurement group_id="B2" value="13"/>
                <measurement group_id="B3" value="48"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Asian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="4"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Black or African American</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
                <measurement group_id="B2" value="7"/>
                <measurement group_id="B3" value="17"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>White</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="52"/>
                <measurement group_id="B2" value="25"/>
                <measurement group_id="B3" value="77"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Other</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="7"/>
                <measurement group_id="B2" value="3"/>
                <measurement group_id="B3" value="10"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Investigators Global Assessment of the Clinical Condition</title>
        <description>The efficacy endpoints for this study consisted of reduction of inflammation as measured by the IGA of the clinical condition. Changes in clinical condition measured as improved, unchanged or worsened.</description>
        <time_frame>Visit 3, day 8</time_frame>
        <safety_issue>No</safety_issue>
        <population>Efficacy Sample, subjects with non-missing data. Day 15 (Visit 3)</population>
        <group_list>
          <group group_id="O1">
            <title>Loteprednol/Tobramycin</title>
            <description>0.5% loteprednol etabonate with 0.3% tobramycin opthalmic suspension administered into affected eye(s) for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>Vehicle used in the study drug administered into affected eye(s) for 14 days</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="63"/>
                  <measurement group_id="O2" value="32"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Investigators Global Assessment of the Clinical Condition</title>
            <description>The efficacy endpoints for this study consisted of reduction of inflammation as measured by the IGA of the clinical condition. Changes in clinical condition measured as improved, unchanged or worsened.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Improved</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="36" lower_limit="44.0" upper_limit="69.5"/>
                  <measurement group_id="O2" value="17" lower_limit="34.7" upper_limit="70.9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Unchanged</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                  <measurement group_id="O2" value="13"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Worse</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Treatment Emergent Adverse Events</title>
        <description>Study eye - Safety Population, At all visits 1,2,3</description>
        <time_frame>day 1, day 8, day 15</time_frame>
        <safety_issue>No</safety_issue>
        <population>Safety population, Study eye</population>
        <group_list>
          <group group_id="O1">
            <title>Loteprednol/Tobramycin</title>
            <description>0.5% loteprednol etabonate with 0.3% tobramycin opthalmic suspension administered into affected eye(s) for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>Vehicle used in the study drug administered into affected eye(s) for 14 days</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="72"/>
                  <measurement group_id="O2" value="36"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Treatment Emergent Adverse Events</title>
            <description>Study eye - Safety Population, At all visits 1,2,3</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Conjunctivitis</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Meibomianitis</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Eyelid edema</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Ocular Signs in the Study Eye - Visit 1</title>
        <description>Lid edema, lid erythema, palpebral conjunctival injection, meibomium plugging measured on a scale of 0-4 none, minimal, mild, moderate, severe.</description>
        <time_frame>Visit 1 (day 1)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Efficacy sample, non-missing data</population>
        <group_list>
          <group group_id="O1">
            <title>Loteprednol/Tobramycin</title>
            <description>0.5% loteprednol etabonate with 0.3% tobramycin opthalmic suspension administered into affected eye(s) for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>Vehicle used in the study drug administered into affected eye(s) for 14 days</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="66"/>
                  <measurement group_id="O2" value="34"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Assessment of Ocular Signs in the Study Eye - Visit 1</title>
            <description>Lid edema, lid erythema, palpebral conjunctival injection, meibomium plugging measured on a scale of 0-4 none, minimal, mild, moderate, severe.</description>
            <units>Units on a scale 0-4</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Lid Edema</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.97" spread="0.84"/>
                  <measurement group_id="O2" value="2.06" spread="0.95"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Lid Erythema</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.98" spread="1.10"/>
                  <measurement group_id="O2" value="1.82" spread="1.22"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Palpebral Conjunctival Injection</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.85" spread="1.13"/>
                  <measurement group_id="O2" value="1.79" spread="0.98"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Meibomian Plugging</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.44" spread="1.04"/>
                  <measurement group_id="O2" value="1.59" spread="1.26"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Ocular Signs in the Study Eye - Visit 2</title>
        <description>Lid edema, lid erythema, palpebral conjunctival injection, meibomium plugging measured on a scale of 0-4 none, minimal, mild, moderate, severe.</description>
        <time_frame>Visit 2 (day 8)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Efficacy population - Study eye</population>
        <group_list>
          <group group_id="O1">
            <title>Loteprednol/Tobramycin</title>
            <description>0.5% loteprednol etabonate with 0.3% tobramycin opthalmic suspension administered into affected eye(s) for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>Vehicle used in the study drug administered into affected eye(s) for 14 days</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="66"/>
                  <measurement group_id="O2" value="32"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Assessment of Ocular Signs in the Study Eye - Visit 2</title>
            <description>Lid edema, lid erythema, palpebral conjunctival injection, meibomium plugging measured on a scale of 0-4 none, minimal, mild, moderate, severe.</description>
            <units>Units on a scale 0-4</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Lid Edema</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.47" spread="0.92"/>
                  <measurement group_id="O2" value="1.38" spread="0.94"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Lid Erythema</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.41" spread="1.01"/>
                  <measurement group_id="O2" value="1.47" spread="1.08"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Palpebral Conjunctival Injection</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.41" spread="1.01"/>
                  <measurement group_id="O2" value="1.16" spread="0.92"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Meibomian Plugging</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.06" spread="1.02"/>
                  <measurement group_id="O2" value="1.00" spread="1.11"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Ocular Signs in the Study Eye - Visit 3</title>
        <description>Lid edema, lid erythema, palpebral conjunctival injection, meibomium plugging measured on a scale of 0-4 none, minimal, mild, moderate, severe.</description>
        <time_frame>Visit 3 (day 15)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Efficacy sample - Study eye</population>
        <group_list>
          <group group_id="O1">
            <title>Loteprednol/Tobramycin</title>
            <description>0.5% loteprednol etabonate with 0.3% tobramycin opthalmic suspension administered into affected eye(s) for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>Vehicle used in the study drug administered into affected eye(s) for 14 days</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="63"/>
                  <measurement group_id="O2" value="32"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Assessment of Ocular Signs in the Study Eye - Visit 3</title>
            <description>Lid edema, lid erythema, palpebral conjunctival injection, meibomium plugging measured on a scale of 0-4 none, minimal, mild, moderate, severe.</description>
            <units>Units on a scale 0-4</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Lid Edema</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.03" spread="0.90"/>
                  <measurement group_id="O2" value="1.41" spread="1.10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Lid Erythema</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.00" spread="0.88"/>
                  <measurement group_id="O2" value="1.50" spread="1.14"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Palpebral Conjunctival Injection</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.11" spread="0.95"/>
                  <measurement group_id="O2" value="1.09" spread="1.09"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Meibomian Plugging</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.86" spread="1.12"/>
                  <measurement group_id="O2" value="1.16" spread="1.22"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>14 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Loteprednol/Tobramycin</title>
          <description>0.5% loteprednol etabonate with 0.3% tobramycin opthalmic suspension administered into affected eye(s) for 14 days</description>
        </group>
        <group group_id="E2">
          <title>Vehicle</title>
          <description>Vehicle used in the study drug administered into affected eye(s) for 14 days</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>bilateral subdural hematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The results of the study may be published or presented by the investigator(s) after the review by, and in consultation and agreement with Bausch &amp; Lomb, and such that confidential or proprietary information is not disclosed.
Prior to publication or presentation, a copy of the final text should be forwarded by the investigator(s) to Bausch &amp; Lomb or its designee, for comment.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Timothy Comstock OD</name_or_title>
      <organization>Bausch &amp; Lomb</organization>
      <phone>(585) 338-6631</phone>
      <email>tcomstock@bausch.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
